Cedar Pollen Allergy - Pipeline Review, H1 2018

March 2018 | 36 pages | ID: CC7E774ED79EN
Global Markets Direct

Abstracts

Cedar Pollen Allergy - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cedar Pollen Allergy - Pipeline Review, H1 2018, provides an overview of the Cedar Pollen Allergy (Immunology) pipeline landscape.

Cedar allergy is a seasonal allergy brought on by an allergic reaction to the pollen from mountain cedar trees. Symptoms include runny nose, itchy and watery eyes, nasal blockage and sneezing. Some suffers also complain of fatigue, mild headache, facial discomfort, sore throat, partial loss of smell and the sensation of ear plugging. Treatment includes antihistamines and decongestants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cedar Pollen Allergy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cedar Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cedar Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy (Immunology).
• The pipeline guide reviews pipeline therapeutics for Cedar Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cedar Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cedar Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cedar Pollen Allergy (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cedar Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Cedar Pollen Allergy - Overview
Cedar Pollen Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cedar Pollen Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cedar Pollen Allergy - Companies Involved in Therapeutics Development
Astellas Pharma Inc
F. Hoffmann-La Roche Ltd
REGiMMUNE Corp
Stallergenes Greer plc
Cedar Pollen Allergy - Drug Profiles
ASP-4070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Cedar Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGI-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STG-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cedar Pollen Allergy - Dormant Projects
Cedar Pollen Allergy - Discontinued Products
Cedar Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference
Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting
Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy
Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cedar Pollen Allergy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cedar Pollen Allergy - Pipeline by Astellas Pharma Inc, H1 2018
Cedar Pollen Allergy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Cedar Pollen Allergy - Pipeline by REGiMMUNE Corp, H1 2018
Cedar Pollen Allergy - Pipeline by Stallergenes Greer plc, H1 2018
Cedar Pollen Allergy - Dormant Projects, H1 2018
Cedar Pollen Allergy - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cedar Pollen Allergy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Astellas Pharma Inc
F. Hoffmann-La Roche Ltd
REGiMMUNE Corp
Stallergenes Greer plc